In this author video, Dr Moore discusses his recently published article in JACS, Differentiating Pathologic from Physiologic Fibrinolysis: Not as Simple as Conventional Thrombelastography.
Watch at: https://t.co/TsmR7ma3XN
@HBuMoore
@edwardljonesII@VAsurgeons@VAECHCS@TShyrJones VA patients are much more appreciative of surgeons and will follow post op instructions. VA system applied to general public not going to have the same result. It’s a patient bias that is unadjusted after regression because these great qualities of the Vets don’t go into model.
@jmsamuelsmd Silliman and Banerjee wanted more experiments. The answer to why the majority of papers in the trauma lab don’t get published in a timely fashion. #hemoglobin#enolase .... list goes on for a while
@JerroldLevy And totally neglected fibrinolysis which was published in JACS months ago. Clear evidence of fibrinolysis shutdown in COVID-19 that progress to multi organ failure
@bryanacotton1 The fellowship model in trauma is the problem. Transplant is the best training to become comfortable with massive bleeding, vascular reconstruction and large incisions. Which is the treatment for the most common cause of preventable death from injury.
@faraonidmd @bhwords@JerroldLevy@isth@NATAforum@bloodmgmt Double the rate of DVT too. Makes biological sense that stopping Fibrinolysis would increase thrombotic complications in a patient population that has never been demonstrated to develop pathologic fibrinolysis. Brings up the question of targeted use in other populations
@bhwords@MarcelLevi Maybe DIC needs to be renamed. Histology supports diffuse micro thrombi driving organ failure in COVID. Where as DIC based on labs is presumptive and few studies definitely slow diffuse microvascular clots